#175 Above Health: The Allergy Clinic of the Future

Most health technology startups chase the wrong problem. They build elegant apps for patients who already manage their conditions well, or create testing panels that measure biomarkers with no clear treatment path. Matt Truebe discovered something different: the real money in healthcare flows to whoever can replace expensive specialists with cheaper practitioners while maintaining quality of care.

Above Health's approach turns traditional allergy care economics upside down. Instead of building another patient app, Truebe uses smart inhalers and connected devices to generate the clinical data that lets nurse practitioners handle cases normally requiring allergists. "So now you can trust maybe a nurse practitioner with remote supervision for patients that have a smart inhaler," Truebe explains. The devices become what he calls a "moat" that enables value-based care contracts with health plans eager to cut specialist costs.

This insight emerged from Truebe's early product failures. His first attempt was a connected food scale for tracking allergen exposure. "No one wants it. Even though I use it, no one wants it," he admits. But when he shifted to smart inhalers, user behavior changed entirely. People actually used the devices and found value in identifying their triggers. More importantly, health plans saw immediate cost reduction potential. "Are they gonna pay a subscription fee every single month? Probably not. But are the health plans interested in reducing costs in the system? Definitely."

The clinical urgency driving this market becomes clear in Truebe's personal story about his daughter's severe allergic reaction. After administering an EpiPen, her condition worsened dramatically. "Ten minutes after the shot, her symptoms got worse. Her O2 dropped to 90, which is near critical," he recalls. In that moment of panic, he faced the terrifying uncertainty that millions of allergy parents experience: not knowing when to escalate care or how to interpret symptoms without specialist guidance. Connected devices promise to fill this knowledge gap by providing real-time data and remote specialist oversight.

The most counterintuitive part of Truebe's strategy involves acquiring physical allergy clinics, not building a pure software play. When investors questioned the capital intensity of clinic ownership, his response was pragmatic: "LA County would not do a deal with us unless we have physical presence." He acquired his first clinic for zero dollars from a retiring allergist, gaining both an existing patient base and the regulatory credibility required for health plan contracts.

This hybrid model reflects a broader shift in healthcare technology. Pure digital health solutions often struggle with reimbursement and clinical integration. By combining hardware data collection, telehealth delivery, and physical clinic presence, Above Health creates what payers actually want to buy: measurable cost reduction with maintained quality.

The testing component reveals another market inefficiency. Truebe argues that most allergy panels waste money on irrelevant biomarkers. "So a lot of other companies, they're offering panels, and half the stuff is not worth it," he says. Above Health's precision approach uses device data, targeted labs, and questionnaires to identify interventions that actually change patient outcomes, not just generate more data.

The real test for Above Health will be scaling this model beyond Los Angeles. Acquiring clinics in each new market requires local relationships, regulatory navigation, and capital deployment that software-only competitors avoid. But if Truebe's thesis proves correct, those barriers become competitive advantages. Health plans want partners who can deliver measurable results, not just digital engagement metrics.

Watch whether other healthtech startups begin acquiring physical assets to credentialize their digital offerings. Above Health's approach suggests that the future of healthcare technology may require more integration with traditional care delivery, not less. The winners will be companies that use technology to make existing clinical workflows more efficient, rather than trying to replace them entirely.